The polymorphism L412F in TLR3 has been associated with several infectious diseases. However, the mechanism underlying this association is still unexplored. Here, we show that the L412F polymorphism in TLR3 is a marker of severity in COVID-19. This association increases in the sub-cohort of males. Impaired macroautophagy/autophagy and reduced TNF/TNFα production was demonstrated in HEK293 cells transfected with TLR3L412F-encoding plasmid and stimulated with specific agonist poly(I:C). A statistically significant reduced survival at 28 days was shown in L412F COVID-19 patients treated with the autophagy-inhibitor hydroxychloroquine (p = 0.038). An increased frequency of autoimmune disorders such as co-morbidity was found in L412F COVID-19 males with specific class II HLA haplotypes prone to autoantigen presentation. Our analyses indicate that L412F polymorphism makes males at risk of severe COVID-19 and provides a rationale for reinterpreting clinical trials considering autophagy pathways. Abbreviations: AP: autophagosome; AUC: area under the curve; BafA1: bafilomycin A1; COVID-19: coronavirus disease-2019; HCQ: hydroxychloroquine; RAP: rapamycin; ROC: receiver operating characteristic; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TLR: toll like receptor; TNF/TNF-α: tumor necrosis factor. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Croci, S., Venneri, M.a., Mantovani, S., Fallerini, C., Benetti, E., Picchiotti, N., et al. (2022). The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males. AUTOPHAGY, 18(7), 1662-1672 [10.1080/15548627.2021.1995152].

The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males

Fallerini C;Benetti E;Imperatore F;Daga S;Montagnani F;Beligni G;Alaverdian D;Spiga O;Baldassarri M;Frullanti E;Mari F;Mirella Bruttini
Membro del Collaboration Group
;
Sara Amitrano
Membro del Collaboration Group
;
Anna Maria Pinto
Membro del Collaboration Group
;
Maria Antonietta Mencarelli
Membro del Collaboration Group
;
Caterina Lo Rizzo
Membro del Collaboration Group
;
Valentina Perticaroli
Membro del Collaboration Group
;
Massimiliano Fabbiani
Membro del Collaboration Group
;
Barbara Rossetti
Membro del Collaboration Group
;
Giacomo Zanelli
Membro del Collaboration Group
;
Elena Bargagli
Membro del Collaboration Group
;
Laura Bergantini
Membro del Collaboration Group
;
Miriana D’Alessandro
Membro del Collaboration Group
;
Paolo Cameli
Membro del Collaboration Group
;
David Bennett
Membro del Collaboration Group
;
Federico Anedda
Membro del Collaboration Group
;
Simona Marcantonio
Membro del Collaboration Group
;
Sabino Scolletta
Membro del Collaboration Group
;
Federico Franchi
Membro del Collaboration Group
;
Maria Antonietta Mazzei
Membro del Collaboration Group
;
Edoardo Conticini
Membro del Collaboration Group
;
Luca Cantarini
Membro del Collaboration Group
;
Bruno Frediani
Membro del Collaboration Group
;
Chiara Spertilli
Membro del Collaboration Group
;
Raffaele Scala
Membro del Collaboration Group
;
Leonardo Croci
Membro del Collaboration Group
;
Silvia Cappelli
Membro del Collaboration Group
;
Agnese Verzuri
Membro del Collaboration Group
;
Agostino Ognibene
Membro del Collaboration Group
;
Alessandra Vergori
Membro del Collaboration Group
;
Arianna Emiliozzi;Serafina Valente
Membro del Collaboration Group
;
Alessia Giorli
Membro del Collaboration Group
;
Lorenzo Salerni
Membro del Collaboration Group
;
Enrico Martinelli
Membro del Collaboration Group
;
Marco Gori
Membro del Collaboration Group
;
Katia Capitani
Membro del Collaboration Group
;
Kristina Zguro
Membro del Collaboration Group
;
Rosangela Artuso
Membro del Collaboration Group
;
Mario Tumbarello
Membro del Collaboration Group
;
Andrea Tommasi
Membro del Collaboration Group
;
Oreste De Vivo
Membro del Collaboration Group
;
Francesca Ariani
Membro del Collaboration Group
;
Elena Andreucci
Membro del Collaboration Group
;
Angelica Pagliazzi
Membro del Collaboration Group
;
Sara Modica
Membro del Collaboration Group
;
Claudio Ferri
Membro del Collaboration Group
;
Valentina Borgo
Membro del Collaboration Group
;
Lucia Vietri
Membro del Collaboration Group
;
Renieri A;Meloni I.
2022-01-01

Abstract

The polymorphism L412F in TLR3 has been associated with several infectious diseases. However, the mechanism underlying this association is still unexplored. Here, we show that the L412F polymorphism in TLR3 is a marker of severity in COVID-19. This association increases in the sub-cohort of males. Impaired macroautophagy/autophagy and reduced TNF/TNFα production was demonstrated in HEK293 cells transfected with TLR3L412F-encoding plasmid and stimulated with specific agonist poly(I:C). A statistically significant reduced survival at 28 days was shown in L412F COVID-19 patients treated with the autophagy-inhibitor hydroxychloroquine (p = 0.038). An increased frequency of autoimmune disorders such as co-morbidity was found in L412F COVID-19 males with specific class II HLA haplotypes prone to autoantigen presentation. Our analyses indicate that L412F polymorphism makes males at risk of severe COVID-19 and provides a rationale for reinterpreting clinical trials considering autophagy pathways. Abbreviations: AP: autophagosome; AUC: area under the curve; BafA1: bafilomycin A1; COVID-19: coronavirus disease-2019; HCQ: hydroxychloroquine; RAP: rapamycin; ROC: receiver operating characteristic; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TLR: toll like receptor; TNF/TNF-α: tumor necrosis factor. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
2022
Croci, S., Venneri, M.a., Mantovani, S., Fallerini, C., Benetti, E., Picchiotti, N., et al. (2022). The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males. AUTOPHAGY, 18(7), 1662-1672 [10.1080/15548627.2021.1995152].
File in questo prodotto:
File Dimensione Formato  
The polymorphism L412F in TLR3-Croci-2022.pdf

accesso aperto

Descrizione: Articolo
Tipologia: PDF editoriale
Licenza: Creative commons
Dimensione 2.46 MB
Formato Adobe PDF
2.46 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1225554